GlassScriptPhysician profile
Kailey Allison Temple
NPI 1427552587
$13,695.69
in general payments reported to CMS, 2019-2025
31 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $3,354 · 2023: $6,440 · 2024: $1,679 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,409 · Consulting Fee: $2,152 · Travel and Lodging: $724 · Education: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,409.02 |
| Consulting Fee | $2,152.00 |
| Travel and Lodging | $723.66 |
| Education | $574.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,346.91 | 2022-2025 | Opzelura |
| Genzyme Corporation | $1,326.11 | 2021-2025 | |
| Abbvie INC. | $1,285.86 | 2021-2025 | |
| Janssen Biotech, INC. | $1,112.97 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $935.64 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $930.17 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $818.89 | 2021-2025 | |
| Leo Pharma INC. | $650.50 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $382.47 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $362.29 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $354.66 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $342.12 | 2021-2025 | |
| Amgen INC. | $245.16 | 2021-2024 | Otezla, Actimmune |
| Dermavant Sciences, INC. | $244.16 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.61 | 2021-2024 | Siliq, Targretin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $188.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.49 | 2023-2024 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $123.97 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $117.29 | 2021-2023 | Xolair, Erivedge |
| Galderma Laboratories, L.P. | $113.32 | 2022-2025 | Aklief, Nemluvio |
| Verrica Pharmaceuticals INC. | $93.99 | 2023-2024 | Ycanth |
| Almirall LLC | $71.59 | 2022-2023 | Klisyri, Seysara |
| Journey Medical Corporation | $65.29 | 2022-2023 | |
| Organon LLC | $64.00 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $43.91 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $38.85 | 2022 | |
| Smith+Nephew, INC. | $32.23 | 2023-2024 | Collagenase Santyl |
| Kyowa Kirin, INC. | $22.84 | 2023 | Poteligeo |
| Fresenius Kabi USA, LLC | $21.39 | 2023 | |
| Epi Health, LLC | $19.04 | 2022 | |
| Biofrontera INC. | $18.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kailey Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.